Genome-wide insights into the shared genetic landscape between metabolic dysfunction-associated fatty liver disease and cardiovascular diseases

Abstract

Background& Aims Multiple epidemiological studies have suggested an association between Metabolic dysfunction-associated fatty liver disease (MAFLD) and cardiovascular diseases (CVDs). However, the genetic components that are shared between the two remain unclear.

Methods This genome-wide pleiotropic association study integrated comprehensive genome-wide association studies (GWAS) summary data from publicly available sources within European populations. It employed a range of genetic approaches to analyze the shared genetic architectures between MAFLD and six CVDs: atrial fibrillation (AF), coronary artery disease (CAD), venous thromboembolism (VTE), heart failure (HF), peripheral artery disease (PAD), and stroke. Initially, we examined the genetic correlation and overlap between these conditions. Subsequently, Mendelian Randomization (MR) analysis was conducted to investigate potential causal relationships. Finally, we explored horizontal pleiotropy at the levels of single nucleotide polymorphisms (SNPs), genes, and biological pathways to further elucidate the shared genetic mechanisms underlying.

Results We observed significant genetic associations between MAFLD and four CVDs, including CAD, HF, PAD, and VTE. However, we noted extensive genetic overlap in all but MAFLD-AF. MR analysis established causal relationships from MAFLD to both AF and PAD. Regarding horizontal pleiotropy, 49 pleiotropic loci were identified at the SNP level with functional annotations, 13 demonstrating strong evidence of colocalization. At the gene level, 14 unique pleiotropic genes were found, with SAMM50 (located at 22q13.31) being particularly notable. Further pathway enrichment analysis indicated that these genes significantly contribute to the pathway of establishment of protein localization to membrane, highlighting their pivotal role in the pathophysiology of both MAFLD and CVD.

Conclusions In all, our research proved the shared genetic architectures and mechanisms between MAFLD and CVD and elucidated their shared genetic etiology and biological mechanisms.

Impact and implications Metabolic dysfunction-associated fatty liver disease (MAFLD) has reached a prevalence of 25-30% worldwide and has emerged as a global leading cause of liver-related morbidity and mortality. Studies have shown that people with MAFLD have a higher risk of cardiovascular disease (CVD) than the general population and there is currently no effective drug to treat the comorbidity of the two, which imposes a burden on the socioeconomic situation and the adverse effects are still rising. Therefore, it is critical to understand how MAFLD affects CVD. Our study provides unique insights into the mechanisms of comorbidity between MAFLD and CVD. The increasing number of complications has prompted us to explore new treatment options, so our study has important clinical significance.

• Download figure
• Open in new tab

Highlights

• The first comprehensive and systematic study to explore the common genetic components between MAFLD and CVD.

• MAFLD and CVDs share genetic architectures and mechanisms.

• Genetically predicted MAFLD increases the risk of AF and PAD.

• The effects of SAMM50 (located at 22q13.31) on lipid metabolism support the comorbidity of MAFLD and CVDs.

• The localization of lipid droplet related contact site proteins to the membrane plays a key role in the comorbidity of MAFLD and CVD.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Financial support statement This study was supported by the Natural Science Foundation of China Excellent Young Scientists Fund (Overseas) (Grant no. K241141101), Guangdong Basic and Applied Basic Research Foundation for Distinguished Young Scholars (Grant no. 2024B1515020047), Shenzhen Pengcheng Peacock Plan, Shenzhen Basic Research General Projects of Shenzhen Science and Technology Innovation Commission (Grant no. JCYJ20230807093514029) (To Y.F.), Shenzhen University 2035 Program for Excellent Research 8690200000314, the Shenzhen Science and Technology Fund for Distinguished Young Scholars (RCYX20231211090127031) (to W. S.), National Natural Science Foundation of China (Grant no. 82230067, 82272103), the Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment (Grant no. 2021B1212040004), and the Natural Science Foundation of Guangdong Province of China (Grant no. 2022B1515020010) (To M.Z.), Shenzhen Science and Technology Program (Grant No. GJHZ20240218111401002 to J.B.), and Center for Computational Science and Engineering at Southern University of Science and Technology. The funder had no role in the design, implementation, analysis, interpretation of the data, approval of the manuscript, and decision to submit the manuscript for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The datasets used in this study are publicly available from the following sources: atrial fibrillation data can be accessed at the GWAS Catalog (GCST006414) through https://www.ebi.ac.uk/gwas/studies/GCST006414; coronary artery disease data are available at https://cvd.hugeamp.org/datasets.html; venous thromboembolism data are accessible at https://www.decode.com/summarydata/; heart failure data can be found at the GWAS Catalog (GCST009541) via https://www.ebi.ac.uk/gwas/studies/GCST009541; peripheral artery disease data are provided at https://cvd.hugeamp.org/datasets.html; stroke data can be obtained at https://www.ebi.ac.uk/gwas/studies/GCST90104539; and metabolic dysfunction-associated fatty liver disease data are available at https://www.ebi.ac.uk/gwas/publications/34841290.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes